1
|
iOvCa241
|
Advanced LGSC
|
Post chemotherapy
|
Cell line
|
34
|
106
|
KRAS (G12D)
|
KRAS: allelic imbalance, CN gain
|
0.30
|
≤ 0.05
|
Sensitive
|
2
|
VOA-1312
|
Advanced LGSC
|
Treatment naïve
|
Cell line
|
35
|
Undetermined
|
KRAS (G12V)
a
|
KRAS: allelic imbalance, CN gain
|
0.50
|
≤ 0.05
|
Sensitive
|
3
|
VOA-8862
|
Advanced LGSC with MP
|
Treatment naïve
|
Cell line
|
66
|
24
|
KRAS (G12D), NRAS (C118Y)
|
KRAS: allelic imbalance, CN gain; NRAS: CN loss; BRAF: alellic imbalance, CN gain
|
5.00
|
≤ 0.05
|
Sensitive
|
4
|
VOA-9164
|
Recurrent LGSC
|
Post anti-hormone therapy
|
Cell line
|
51
|
33
|
KRAS (G12V)
|
KRAS: allelic imbalance, CN gain; NRAS: CN loss; BRAF: high CN gain
|
0.30
|
≤ 0.05
|
Sensitive
|
5
|
VOA-1056
|
Advanced MPSBT with invasive implants
|
Treatment naïve
|
Cell line
|
1
|
75
|
NRAS (Q61R)
|
NRAS: CN gain
|
0.30
|
≤ 0.05
|
Resistant
|
VOA-3993
|
Recurrent LGSC
|
Post anti-hormone therapy
|
Cell line
|
16
|
84
|
NRAS (Q61R)
|
KRAS: allelic imbalance, CN gain; NRAS: CN gain
|
5.42
|
≤ 0.05
|
Resistant
|
6
|
VOA-3448
|
Recurrent LGSC with MP
|
Post chemotherapy and anti-hormone therapy
|
Cell line
|
39
|
78
|
Wild type
|
BRAF: CN gain
|
0.58
|
≤ 0.05
|
Resistant
|
VOA-3723
|
Recurrent LGSC with MP
|
Post chemotherapy and anti-hormone therapy
|
Cell line
|
40
|
96
|
Wild type
|
None
|
1.00
|
≤ 0.05
|
Resistant
|
7
|
VOA-4627
|
Recurrent LGSC
|
Post chemotherapy, anti-hormone therapy, and targeted therapy
|
Cell line
|
56
|
111
|
Wild type
|
KRAS: CN gain; BRAF: LOH
|
8.75
|
0.08
|
Resistant
|
VOA-4698
|
Recurrent LGSC
|
Post chemotherapy, anti-hormone therapy, and targeted therapy
|
Cell line
|
50
|
110
|
Wild type
|
KRAS: CN gain; NRAS: CN gain; BRAF: LOH
|
11.67
|
0.08
|
Resistant
|
8
|
VOA-6406
|
Advanced LGSC
|
Post chemotherapy
|
Cell line
|
23
|
80
|
NRAS (Q61R)
|
NRAS: CN gain
|
0.64
|
≤ 0.05
|
Resistant
|
9
|
VOA-6857
|
Recurrent LGSC
|
Post chemotherapy, anti-hormone therapy, and MEKi therapy
|
Transient culture
|
27
|
83
|
Wild type
|
None
|
n/a
|
n/a
|
n/a
|
10
|
VOA-7604
|
Advanced LGSC with SBT
|
Treatment naïve
|
Transient culture
|
25
|
61
|
Wild type
|
KRAS: allelic imbalance, CN gain
|
n/a
|
n/a
|
n/a
|
11
|
VOA-6800
|
Advanced LGSC
|
Post chemotherapy
|
Transient culture
|
29
|
68
|
BRAF (D594G)
|
None
|
n/a
|
n/a
|
n/a
|